EP Patent

EP1956000B1 — Acylating agents useful for acylating peptides

Assigned to Novo Nordisk AS · Expires 2016-10-05 · 10y expired

What this patent protects

The present invention relates to compounds useful as acylating agents in a method where one or more acyl groups are introduced into a peptide or a protein. More particularly the invention relates to compounds useful as acylating agents in an improved method of acylating the e-ami…

USPTO Abstract

The present invention relates to compounds useful as acylating agents in a method where one or more acyl groups are introduced into a peptide or a protein. More particularly the invention relates to compounds useful as acylating agents in an improved method of acylating the e-amino group of a lysine residue contained in a naturally occurring GLP-1 or an analogue thereof.

Drugs covered by this patent

Patent Metadata

Patent number
EP1956000B1
Jurisdiction
EP
Classification
—
Expires
2016-10-05
Drug substance claim
No
Drug product claim
No
Assignee
Novo Nordisk AS
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.